CFO4Life Group LLC Has $617,000 Stake in Amgen Inc. (NASDAQ:AMGN)

CFO4Life Group LLC grew its position in Amgen Inc. (NASDAQ:AMGN) by 4.0% during the 1st quarter, Holdings Channel.com reports. The firm owned 2,169 shares of the medical research company’s stock after purchasing an additional 84 shares during the period. CFO4Life Group LLC’s holdings in Amgen were worth $617,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Kades & Cheifetz LLC grew its position in Amgen by 24.8% during the first quarter. Kades & Cheifetz LLC now owns 1,010 shares of the medical research company’s stock worth $287,000 after buying an additional 201 shares in the last quarter. Gallacher Capital Management LLC grew its position in Amgen by 5.7% during the first quarter. Gallacher Capital Management LLC now owns 1,006 shares of the medical research company’s stock worth $286,000 after buying an additional 54 shares in the last quarter. Advisory Services Network LLC grew its position in Amgen by 33.9% during the first quarter. Advisory Services Network LLC now owns 27,390 shares of the medical research company’s stock worth $7,788,000 after buying an additional 6,935 shares in the last quarter. Oxbow Advisors LLC grew its position in Amgen by 37.1% during the first quarter. Oxbow Advisors LLC now owns 1,108 shares of the medical research company’s stock worth $315,000 after buying an additional 300 shares in the last quarter. Finally, Flossbach Von Storch AG bought a new stake in Amgen during the first quarter worth $215,000. Institutional investors and hedge funds own 76.50% of the company’s stock.

Insider Activity at Amgen

In related news, SVP Nancy A. Grygiel sold 2,117 shares of the firm’s stock in a transaction dated Friday, May 3rd. The shares were sold at an average price of $313.09, for a total value of $662,811.53. Following the transaction, the senior vice president now owns 9,883 shares of the company’s stock, valued at approximately $3,094,268.47. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. 0.69% of the stock is owned by insiders.

Amgen Stock Up 2.6 %

Shares of AMGN traded up $8.34 during trading hours on Friday, hitting $333.43. The stock had a trading volume of 1,159,264 shares, compared to its average volume of 2,708,972. The company has a debt-to-equity ratio of 11.96, a current ratio of 1.42 and a quick ratio of 0.98. The firm has a 50 day simple moving average of $308.79 and a 200-day simple moving average of $294.36. The firm has a market capitalization of $178.86 billion, a P/E ratio of 46.88, a price-to-earnings-growth ratio of 2.91 and a beta of 0.58. Amgen Inc. has a 1-year low of $224.34 and a 1-year high of $333.85.

Amgen (NASDAQ:AMGN) last issued its earnings results on Thursday, May 2nd. The medical research company reported $3.96 EPS for the quarter, beating the consensus estimate of $3.76 by $0.20. Amgen had a return on equity of 156.21% and a net margin of 12.74%. The company had revenue of $7.45 billion during the quarter, compared to the consensus estimate of $7.45 billion. During the same period last year, the business posted $3.98 EPS. The firm’s revenue for the quarter was up 22.0% compared to the same quarter last year. Sell-side analysts predict that Amgen Inc. will post 19.47 EPS for the current fiscal year.

Wall Street Analyst Weigh In

AMGN has been the subject of a number of research reports. Morgan Stanley dropped their price target on Amgen from $310.00 to $303.00 and set an “equal weight” rating for the company in a research note on Thursday. William Blair raised Amgen from a “market perform” rating to an “outperform” rating in a research report on Friday, May 3rd. UBS Group raised their target price on Amgen from $284.00 to $307.00 and gave the stock a “neutral” rating in a research report on Friday, May 3rd. Truist Financial reaffirmed a “buy” rating and set a $320.00 target price on shares of Amgen in a research report on Friday, April 12th. Finally, Royal Bank of Canada raised their target price on Amgen from $328.00 to $332.00 and gave the stock an “outperform” rating in a research report on Friday, June 14th. Ten equities research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $307.00.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.